Collaboration and License Agreements - Contract Assets and Liabilities (Details) - USD ($) $ in Thousands		3 Months Ended
	Dec. 26, 2020	Jun. 30, 2022	Mar. 31, 2022
Deferred Revenue
Deferred revenue, current		$ 100,564	$ 100,564
Deferred revenue, non-current		350,565	375,706
Cost Cash Advance from Collaboration Partner
Beginning balance		33,818
Additions	$ 146,400	0
Imputed Interest		568
Cost share advance from collaboration partner, current		8,555	33,818
Collaboration expense to Pfizer
Deferred Revenue
Beginning balance		476,270
Additions		0
Imputed Interest		0
Deductions		(25,141)
Ending balance		451,129
Deferred revenue, current		100,600	100,600
Deferred revenue, non-current		350,600	$ 375,700
Cost Cash Advance from Collaboration Partner
Deductions		(25,831)
Ending balance		$ 8,555